Lenograstim
From Wikipedia, the free encyclopedia
|
Lenograstim
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | L03 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as a immunostimulator.[1]
[edit] References
- ^ Amadori S, Suciu S, Jehn U, et al (2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood 106 (1): 27–34. doi:. PMID 15761020.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||
|
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
